Latest Impairments News

ECS Botanics boosted revenue by 10% to $21.4 million in FY26, delivering positive EBITDA and operating cash flow while advancing international market entry and branded product growth.

Frontier Digital Ventures narrowed its focus to core classifieds, resulting in a 27% revenue decline but an 18% rise in EBITDA and a $2.5 million profit in the first half of 2026.

Talius Group’s HY2026 results reveal a strategic pivot towards higher-margin software subscriptions, with gross margin surging to 51% despite a 19% revenue dip due to hardware deployment timing. Active subscriptions topped 53,200, underpinning a $3.26 million ARR, while cash burn shrank dramatically.

LTR Pharma is shifting gears from clinical trials to commercial rollout, securing US partnerships for ROXUS and reporting encouraging SPONTAN Phase II data that supports FDA approval ambitions.

Elevra Lithium posted a $44 million profit in FY26 after merging Sayona Mining and Piedmont Lithium, overcoming temporary mining challenges and securing full funding for the North American Lithium expansion.

Delegat Group (NZX:DGL) reported a 20% jump in operating NPAT to NZD 61.5 million for FY26, driven by record EBITDA and a 4% rise in global case sales. The Board declared a 22-cent dividend, up 10%, while net debt fell by NZD 51.8 million.

Synlait Milk anticipates a modest improvement in underlying EBITDA for FY26 but expects a substantial net loss after tax, reflecting ongoing operational challenges and a tough first half.

Dubber Corporation Limited (ASX:DUB) posted a 17% revenue drop in FY26 to $35.1 million, mainly due to a major contract loss in Europe, but narrowed its net loss by 78% excluding impairments and achieved cash flow breakeven in H2.

Nuchev Limited grew revenue by 12% in FY26, driven by domestic expansion, yet saw margins contract and adjusted EBITDA losses deepen to A$4.6 million. The company’s FY27 focus shifts to margin improvement, operating leverage, and cash conversion.

Actinogen Medical reported a $15.38 million loss for FY2026 while progressing its lead Alzheimer's drug Xanamem toward pivotal trial results expected this November. The company secured regulatory alignment and strengthened its cash position to fund operations through mid-2027.

Transmetro Corporation lifted its net profit after tax by nearly 50% to $4.489 million for FY26, driven by a 10.4% revenue increase and a 23.4% jump in EBITDA. The hospitality operator also raised its fully franked final dividend to 6 cents per share.

Biotron Limited posted a $1.52 million net loss for FY2026, driven by integration and R&D costs following its Sedarex acquisition, while progressing regulatory and clinical development for its SedRxTM anaesthetic and antiviral pipeline.